Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations

REFERENCES

• Lampe F, Gatell J, Stasewski S, et al. Trends over time in initial virological failure of first HAART, 1996 to 2002: a joint cohort analysis of 4143 subjects [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
   Google Scholar
• Bartlett JA, Fath MJ, DeMasi R, et al. An updated system-atic overview of triple combination therapy in antiretroviral-naive HIV-infected adults [abstract]. In: Program and ab-stracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
   Google Scholar
• Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fu-sion inhibitor enfuvirtide: consensus recommendations. AIDS. 2004;18:1137–1146.
   PubMed Web of Science ®Google Scholar
• Pozniak A, Gazzard B, Anderson J, et al. British HIV Asso-ciation (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2003;4(Suppl 1):1–41.
   PubMedGoogle Scholar
• US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (The living document, October 29,2004). 2005. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_100605.pdf.
   Google Scholar
• Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251–265.
   PubMed Web of Science ®Google Scholar
• Robbins GK, De G, V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293–2303.
   PubMed Web of Science ®Google Scholar
• Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304–2315.
   PubMed Web of Science ®Google Scholar
• Cooper D, Yeni P. Virological and Immunological out-comes at 3 years following initiation of ART with regimens containing a NNRTI or PI or both. The INITIO trial [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
   Google Scholar
• MacArthur RD, Chen L, Mayers DL, et al. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials. 200122: 176–190.
   Google Scholar
• MacArthur RD, Chen L, Peng G, et al. Efficacy and safety of ABC+3TC versus ddl+d4T when combined with a PI, NNRTI or both in AR-naive persons on their first HAART Regimen: the NRTI substudy of the CPCRA 058 FIRST Study [abstract]. Antivir Ther. 2003;8:5333–5334.
   Google Scholar
• Lichterfeld M, Wohrmann A, Schmeisser N, et al. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. EurJ Med Res. 2003;8:56–60.
   PubMed Web of Science ®Google Scholar
• Eron J, da Silva B, King M, et al. Lopinavir/ritonavir in antiretroviral-naive HIV-infected patients: 5-year follow-up [abstract]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Che-motherapy; 2004.
   Google Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039–2046.
   PubMed Web of Science ®Google Scholar
• Kempf DJ, King MS, Bernstein B, et al. Incidence of resis-tance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51–60.
   PubMed Web of Science ®Google Scholar
• MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS. 2004;18:651–655.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Bilello JA, Stein DS, et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis. 1998;178:360–367.
   PubMed Web of Science ®Google Scholar
• Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483–489.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services (DHHS). Guide-lines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2005. Available at: http://aidsinfo.nih.gov/guidelines. Accessed March 20, 2006.
   Google Scholar
• Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among indi-viduals infected with HIV in the United Kingdom: multicentre cohort study. BMJ. 2005;330:695.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immu-nodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phe-notypic drug susceptibility with virologic outcome. J Infect Dis. 1999;179:1375–1381.
   PubMed Web of Science ®Google Scholar
• Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345:398–407.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002288: 169–180.
   Google Scholar
• Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000; 182:1375–1384.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Harrigan PR, Jahnke N, et al. Multiple drug rescue therapy for HIV-infected individuals with prior viro-logic failure to multiple regimens. AIDS. 200115: 61–69.
   Google Scholar
• Montaner JS, Mellors JW. Antiretroviral therapy for previ-ously treated patients. N Engl J Med. 2001;345:452–455.
   PubMed Web of Science ®Google Scholar
• Struble K, Murray J, Cheng B, Gegeny T, Miller V, Gulick R. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS. 2005; 19:747–756.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Antiviral Drugs Advisory Committee, January 11, 2001. Available at: http://www.fda.gov/oashi/aids/advisorycom.html#2001. Ac-cessed 2005.
   Google Scholar
• Sista P, Melby T, Dhingra U, et al. The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse tran-scriptase and protease inhibitors and non-B clades [ab-stract]. Antivir Ther. 2001;6: 3–4.
   PubMedGoogle Scholar
• Delfraissy J-F, Montaner J, Eron J, et al. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 Phase III trials in highly antiretroviral (ARV) treatment-experienced patients [abstract]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003.
   Google Scholar
• Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized back-ground regimen only 1 and 2 clinical trials. J Acquir Im-mune Defic Syndr. 2005;40:404–412.
   PubMed Web of Science ®Google Scholar
• Arastéh K, Lazzarin A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evalua-tion of enfuvirtide with an optimized background regimen [abstract]. Proceedings of the XV International AIDS Con-ference. 2004;197–201.
   Google Scholar
• Youle M, Cohen C, Katlama C, Kuritzkes D, Walmsley S. Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. Lancet. 2004;364:1036–1037.
   PubMed Web of Science ®Google Scholar
• Miralles GD, DeMasi R. Virologic suppression of an active boosted PI regimen is significantly enhanced by the addi-tion of a fusion inhibitor in treatment-experienced patients [abstract]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Disease Society of America; 2004.
   Google Scholar
• Haubrich R, DeMasi R, Thommes JA. Improved virologic response in three-class experienced patients when an ac-tive boosted protease inhibitor is combined with enfuvirtide (ENF) [abstract]. In: Program and abstracts of the 43rd Annual Meeting of IDSA; 2005.
   Google Scholar
• Hicks C. RESIST-1: a Phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data [abstract]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004.
   Google Scholar
• Cahn P. 24-week data from RESIST 2: Phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV+ patients [abstract]. In: Program and abstracts of the 7th Interna-tional Congress on Drug Therapy in HIV Infection; 2004.
   Google Scholar
• Cooper D, Hicks C, Cahn P, et al. 24-week RESIST Study analyses: the efficacy of tipranavir/ritonavir (TPV/r) is supe-rior to lopinavir/ritonavir (LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) [abstract]. In: Program and abstracts of the 12th Confer-ence on Retroviruses and Opportunistic Infections; 2005.
   Google Scholar
• Cahn P, Hicks C. RESIST-1 (R-1) and RESIST-2 (R-2) 48-week meta-analysis demostrate superiority of protease in-hibitor (P1) tipranavir+ritonavir (TPV/r) over an optimised comparator PI (CPI/r) regimen in antiretroviral (ARV) experi-enced patients. In: Program and abstracts of the 10th European AIDS Conference; Dublin, Ireland. Abstract LBPS3/8.
   Google Scholar
• Schapiro J, Cahn P, Trottier B, et al. Effect of baseline genotype on response to tipranavir/ritonavir compared with standard-of-care comparator in treatment-experi-enced patients: The Phase 3 RESIST-1 and -2 Trials [ab-stract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals I. Tipranavir: Antivi-ral Drugs Advisory Committee Briefing Document. 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4139b1-02-boehringer.pdf
   Google Scholar
• Hill A, Moyle G. Relative antiviral efficacy of TMC114/r and tipranavir/r versus control PI in the POWER and RESIST trials [abstract]. In: Program and abstracts of the 12th Annual Conference of the British HIV Association (BHIVA); 2006.
   Google Scholar
• D'Aquila R, Schapiro J, Brun-Vézinet F, et al. Drug resis-tance mutations in HIV-1. Top HIV Med. 2003;11:92–96.
   PubMedGoogle Scholar
• Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment op-tions: 24-week planned interim analysis of 2 96-week mul-tinational dose-finding trials [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Op-portunistic Infections; 2005.
   Google Scholar
• Katlama C, Carvalho M, Cooper D, et al. POWER: TMC114-C213 study - week 24 analysis [abstract]. In: Program and abstracts of the 3rd International AIDS Soci-ety Conference; 2005.
   Google Scholar
• Wilkin T, Haubrich R, Steinhart C, et al. POWER 2 (TMC114-C202) week 24 efficacy analysis. Poster pre-sented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16–19, 2005; Washington, DC, USA. Poster 2860.
   Google Scholar
• Berger D, Bellos N, Farthing C, et al. TMC114/r in 3-class-experienced patients: 24-week primary safety analysis of the POWER 2 study (TMC114-C202). In: Poster presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16–19, 2005; Washington, DC, USA. Poster H–1094.
   Google Scholar
• Montaner J, Guimaraes D, Chung J, Gafoor Z, Salgo M, DeMasi R. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials. 2005;6:281–290.
   PubMed Web of Science ®Google Scholar
• Martin D, Jacobson J, Schurmann D, et al. PA-457, the first-in-class maturation inhibitor, exhibits antiviral activity following a single oral dose in HIV-1-infected patients [ab-stract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
   Google Scholar
• Little S, Drusano G, Schooley R, et al. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1-infected patients [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005.
   Google Scholar
• Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896–1905.
   PubMed Web of Science ®Google Scholar
• Menzo S, Castagna A, Monachetti A, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother. 2004;48:3253–3259.
   PubMed Web of Science ®Google Scholar